Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyGiancarlo Comi, O. R. Hommes, Massimo Filippi et al.|The Lancet|2001Cited by 1.1k
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O’Connor, Timon Bogumil, Massimo Filippi et al.|The Lancet Neurology|2009Cited by 403
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalbán, Heinz Wiendl, Christine Lebrun‐Frénay et al.|The Lancet Neurology|2025Cited by 314
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis opticaPatrick Waters, Romain Marignier, Markus Reindl et al.|Journal of Neurology Neurosurgery & Psychiatry|2016Cited by 297
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, Erik Wallström, David K.B. Li et al.|The Lancet Neurology|2013Cited by 233